Cathepsin B - Pipeline Review, H2 2020

Summary

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Cathepsin B - Pipeline Review, H2 2020, outlays comprehensive information on the Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Cathepsin B (CatB) is an enzymatic protein belonging to the peptidase. It promotes hydrolysis of proteins with broad specificity for peptide bonds. It cleaves -Arg-Arg- - -Xaa bonds in small molecule substrates. In addition to being an endopeptidase, shows peptidyl-dipeptidase activity, liberating C-terminal dipeptides. The molecules developed by companies in Phase 0, Preclinical and Discovery stages are 1, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Infectious Disease, Gastrointestinal and Immunology which include indications Alzheimer's Disease, Autoimmune Disorders, Cancer Pain, Ebolavirus Infections (Ebola Hemorrhagic Fever), Glioblastoma Multiforme (GBM), Liver Fibrosis, Neuropathic Pain (Neuralgia), Pancreatic Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Schistosomiasis mansoni Infections and Traumatic Brain Injury.

Furthermore, this report also reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)
• The report reviews Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics and enlists all their major and minor projects
• The report assesses Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics

Reasons to Buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope